Fore C Investment takes over LU Holding’s shareholding and becomes the new fourth major shareholder of BPC Instruments
BPC Instruments AB (“BPC” or the “Company”) announces that Fore C Investment (“Fore C”) has made an agreement with LU Holding AB (“LU Holding”) and acquired its entire shareholding in BPC. Fore C thus becomes the new fourth major shareholder and holds 4.2 percent of ownership in BPC.
Fore C is a Swedish private investment company owned by Göran Nordlund. The company has more than 20 years experience in investing in entrepreneur-led companies. Fore C believes in long-term business value creation through hard work driven by a strong entrepreneurship spirit. LU Holding is Lund University’s investment company, which holds equity in approximately 60 companies based on knowledge and research from Lund University. LU Holding has been one of the co-founders since the establishment of BPC back in 2005.
CEO at BPC, Dr. Jing Liu, comments:
“It has been a very constructive and extraordinary partnership with LU Holding since the beginning of our business journey. I am grateful to LU Holding’s team for their endless trust and professional support throughout these years. I hope BPC has become a successful case in LU Holding’s company portfolio and a good reference for encouraging more ambitious scientists and engineers to commercialize their innovative ideas. I am certainly looking forward to having close cooperation with Fore C’s team for a long-term continuous value development of BPC. Most welcome to join us on this exciting development journey.”
Göran Nordlund at Fore C Investment, comments:
“It is with great enthusiasm that we invest in BPC through our subsidiary Fore C Micro AB, managed by our portfolio manager Filip Helmroth. We believe that BPC is posed for a long time of profitable high growth. BPC is a typical company that we want to invest in: a great entrepreneur, an underlying market growth, and an offensive growth business plan. We look forward to supporting BPC for the long run as an engaged shareholder.”
CEO at LU Holding, Christine Widstrand, comments:
“It has been a great pleasure to support and follow BPC’s fantastic development since its inception. Now, we are proud to be able to sell out our shares to a long-term and committed new owner. Through this exit, we get the opportunity to get involved in new exciting commercialization projects from Lund University.”
For more information regarding BPC Instruments, please contact:
BPC Instruments AB
Dr. Jing Liu, CEO
Tel: +46 (0) 46 16 39 51
E-mail: [email protected]
This information is such information that BPC Instruments AB is obliged to publish in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, through the agency of the contact person above, for publication on 1th February, 2023.
About BPC Instruments AB
BPC Instruments is a global Swedish-based pioneering technology company developing and offering analytical instruments enabling more efficient, reliable, and higher quality of research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also significant reduction in time consumption and labour requirement for performing analysis. BPC Instruments’ innovative products offer high quality hardware and software based on deep knowledge and experience of target applications. The solutions are the first of their kind, making the company a pioneer in its field. Today, BPC Instruments exports to 60+ countries around the world. BPC is listed on Spotlight Stock Market in Sweden. For more information, please visit BPC’s webpage: www.bpcinstruments.com
Breakthrough in plant-based production of Cyxone’s T20K
Cyxone (publ), a biotech company in autoimmune diseases, is developing T20K which acts to stop or slow down the progression of Multiple Sclerosis (MS). Researchers at the well renowned Center of Excellence for Innovations in Peptide and Protein Science, Australia have demonstrated a breakthrough in...
Genombrott för växtbaserad produktion av Cyxones T20K
Cyxone (publ), ett bioteknikföretag inom autoimmuna sjukdomar, utvecklar T20K som verkar för att stoppa eller bromsa utvecklingen av multipel skleros (MS). Forskare vid erkända Center of Excellence for Innovations in Peptide and Protein Science, i Australien har gjort ett genombrott kring växtbasera...
Today is the final day for subsciribing to shares in aXichem’s rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DIS...
Idag är sista teckningsdag i aXichems företrädesemission
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLE...